On 24 October 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced that it has approved Novo Nordisk’s Alhemo® (concizumab) for the prevention or reduction in the frequency of bleeding episodes (prophylaxis) in people aged 12 years and older with haemophilia A or B with inhibitors. The market authorisation was granted on 6 October 2025.
In addition to the UK, Alhemo® is currently approved in Canada (March 2023), Australia (July 2023), Switzerland (August 2023), Japan (September 2023), the US (December 2024) and the EU (December 2024).